NetworkNewsBreaks – Cybin Inc. (NYSE American: C
Post# of 341
(Total Views: 152)
Posted On: 03/09/2022 3:50:55 PM
NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Eyes Potential of First-of-Its-Kind Study
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), recently secured approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. The Institution Review Board (“IRB”) granted the approval, which gives a green light to a Cybin-sponsored study designed around Kernel’s quantitative neuroimaging technology, Kernel Flow. The technology uses pulsed light instead of continuous wave light to increase measured brain information. The Flow device is a wearable helmet, in contrast to electroencephalography (“EEG”) electrodes that usually require the application of gel or functional magnetic resonance imaging (“fMRI”) studies that require lying in a scanner. As a result, the novel device holds potential for wide application in neuroscientific or physiological studies of brain activity during psychedelic use. To date, direct neuroimaging research of psychedelic effects is rare and has never been attempted with a wearable device. “We believe the results of this study will lead to future studies that will test the effectiveness of psychedelic treatments and will further support our mission to develop psychedelics into therapeutics,” a recent article quotes Cybin CEO Doug Drysdale as saying. “We still have much to learn about what is occurring in the brain during a psychedelic experience. This first-of-its-kind, Cybin-sponsored study using the Kernel Flow device aims to expand our physiological understanding of psychedelic pharmacotherapy. We are excited to be part of this pioneering journey with our partners at Kernel.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), recently secured approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. The Institution Review Board (“IRB”) granted the approval, which gives a green light to a Cybin-sponsored study designed around Kernel’s quantitative neuroimaging technology, Kernel Flow. The technology uses pulsed light instead of continuous wave light to increase measured brain information. The Flow device is a wearable helmet, in contrast to electroencephalography (“EEG”) electrodes that usually require the application of gel or functional magnetic resonance imaging (“fMRI”) studies that require lying in a scanner. As a result, the novel device holds potential for wide application in neuroscientific or physiological studies of brain activity during psychedelic use. To date, direct neuroimaging research of psychedelic effects is rare and has never been attempted with a wearable device. “We believe the results of this study will lead to future studies that will test the effectiveness of psychedelic treatments and will further support our mission to develop psychedelics into therapeutics,” a recent article quotes Cybin CEO Doug Drysdale as saying. “We still have much to learn about what is occurring in the brain during a psychedelic experience. This first-of-its-kind, Cybin-sponsored study using the Kernel Flow device aims to expand our physiological understanding of psychedelic pharmacotherapy. We are excited to be part of this pioneering journey with our partners at Kernel.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)